ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models.

by Amanda Hanson, Kutlu Elpek, Ellen Duong, Lindsey Shallberg, Martin Fan, Calvin Johnson, Matthew Wallace, George R Mabry, Stephen Sazinsky, Lauren Pepper, Chengyi J Shu, Sriram Sathyanarayanan, Sarah Zuerndorfer, Tyler Simpson, Monica Gostissa, Michael Briskin, Deborah Law, Jennifer Michaelson, Christopher J Harvey
Published 2020-01-01